Elham Neisani Samani

Dr. Elham Neisani Samani


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2019 in Cureus
Verified
Journal Article
Open access
PDF file
YSyasar sattar
yasar sattar
ESElham Neisani Samani
Elham Neisani Samani
FZFnu Zafrullah
Fnu Zafrullah
SLSharaad Latchana
Sharaad Latchana
NPNirav B. Patel
Nirav B. Patel
Heart failure (HF) is the fourth-most frequent cause of death and remains a challenge for public health. Therapy goals for HF with reduced ejection fraction (HFrEF) are the improvement in the quality of life, prolonged survival, a reduction of signs and symptoms, and the prevention of hospitalization. Angiotensin-converting enzyme inhibitors, beta-blockers, and mineralocorticoid receptor antagonists are the treatments of choice for HFrEF. Although ivabradine is not available in all countries, it is likely a new promising approach to improve outcomes in patients with HFrEF, either alone or with beta-blockers. Here, we review the current knowledge about ivabradine in HFrEF and assess its effect on outcomes in HF.

4 December 2022 in Cureus
Verified
Journal Article
Open access
ESElham Neisani Samani
Elham Neisani Samani
MHMelina M. Henderson
Melina M. Henderson
HSHamid Sanjaghsaz
Hamid Sanjaghsaz
RNRonald Nichols
Ronald Nichols
Ectopic pregnancy continues to be the leading cause of death in the first trimester. Here, we report the case of a 17-year-old female who presented with vaginal bleeding and a positive serum beta-human chorionic gonadotropin level. In addition, we review the literature, focusing on the early diagnosis and management with the increasing preference for nonsurgical management of ectopic pregnancy, particularly in adolescents.